In patients with metastatic anaplastic thyroid cancer who have progressed on chemotherapy — who have a poor prognosis —a new combination of nonchemotherapy drugs shows promise. The combination of the multikinase inhibitor lenvatinib with the immunotherapy pembrolizumab has shown durable responses and encouraging survival rates in a small clinical trial. “Our results indicate that a combination of […]